Jean-Pierre Latere, EsoBiotec CEO
March 17, 2025 06:33 AM EDTUpdated 06:47 AM
Deals
Cell/Gene Tx

As­traZeneca to buy cell ther­a­py start­up for $425M up­front

Elizabeth Cairns

Senior biopharma journalist

As­traZeneca said Mon­day that it has agreed to ac­quire a cell ther­a­py biotech found­ed just four years ago for an up­front pay­ment of $425 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s HHS de­fends Biden-era stance on 340B re­bate mod­els

FDA staff re­turn to White Oak cam­pus en masse af­ter Trump ad­min­is­tra­tion push

In­cyte's stock sinks as piv­otal skin dis­ease da­ta dis­ap­point

Post-Hoc: Kennedy's an­ti-vac­cine ac­tions should­n't sur­prise any­one

George Church spin­out de­vel­op­ing ge­nom­i­cal­ly re­cod­ed or­gan­isms cuts most em­ploy­ees

As­traZeneca taps Al­teogen in deal worth more than $1.3B to make sub­cu­ta­neous can­cer drugs

A service from the Financial Times